CLINICAL_TRIALS
trial_result
· 2013-02-11
Clinical Trial Update: FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Summary
Phase 2 trial update showing completion of FR901228 (romidepsin) in relapsed or refractory Non-Hodgkin lymphoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma | Phase 2 | Status: COMPLETED